Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
AHARONI v. ENZYMOTEC LTD. et al
Case Number:
2:14-cv-05556
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
- Bank of America Corp.
- Canaccord Genuity Group Inc.
- Enzymotec Ltd.
- Jefferies Financial Group Inc.
- Wedbush Securities Inc.
- Wells Fargo & Co.
Sectors & Industries:
-
April 03, 2017
Enzymotec Settles IPO Stock-Drop Suit For $6.5M
Israeli biotech company Enzymotec Ltd. and a putative class of shareholders have reached a $6.5 million settlement and asked a New Jersey federal judge on Friday to recognize the class and give the deal preliminary approval.
-
December 15, 2015
Enzymotec Can't Shake Shareholder Suit Over $70M IPO
A New Jersey federal judge on Tuesday upheld most claims in a suit alleging Enzymotec Ltd. misrepresented its potential profitability ahead of an estimated $70 million initial public offering, saying shareholders provided sufficient evidence the Israeli biotechnology and health products company knew certain statements were false.
-
November 06, 2014
Enzymotec Investors Want Suits Over $70M IPO Combined
Shareholders suing Israeli biotechnology and health products company Enzymotec Ltd. for allegedly misrepresenting the company's potential profitability ahead of its estimated $70 million initial public offering last year asked a New Jersey federal court Wednesday to consolidate multiple cases.
-
September 09, 2014
Class Suit Accuses Enzymotec Of Lying Before Its $70M IPO
Israeli biotechnology and health products company Enzymotec Ltd. was hit with a putative securities class action in New Jersey federal court Friday, alleging it defrauded investors by misrepresenting the company's potential profitability ahead of its estimated $70 million initial public offering last year.